Dexilant and Methotrexate Interaction
Proton pump inhibitors (PPIs) like dexlansoprazole (Dexilant) can potentially decrease methotrexate clearance and increase toxicity risk, particularly at high doses (>30 mg/week), though this interaction is primarily documented with high-dose methotrexate rather than the low-dose weekly regimens typically used for inflammatory conditions.
Understanding the Interaction Mechanism
The FDA updated methotrexate labeling based on accumulating evidence showing that PPIs—including omeprazole, esomeprazole, and pantoprazole—may decrease methotrexate clearance, leading to elevated serum levels of methotrexate and/or its metabolite hydroxymethotrexate 1. This can potentially result in methotrexate toxicities including myelosuppression, hepatotoxicity, and renal dysfunction.
The interaction appears to be dose-dependent, with most documented cases involving high-dose methotrexate (typically >100 mg/m² used in oncology) rather than the low-dose weekly regimens (7.5-25 mg/week) used for psoriasis and rheumatoid arthritis 2, 1.
Clinical Significance for Low-Dose Methotrexate
For patients on low-dose methotrexate (≤30 mg weekly) for inflammatory conditions:
- The clinical significance of this interaction remains uncertain and likely minimal in most patients
- No major guidelines for psoriasis or rheumatoid arthritis specifically contraindicate PPI use with low-dose methotrexate 2, 3
- The 2020 AAD-NPF guidelines acknowledge drug interactions as a risk factor but do not single out PPIs as contraindicated 2
Risk Stratification and Management
High-risk patients who warrant closer monitoring when combining Dexilant with methotrexate include those with:
- Renal insufficiency (creatinine clearance <50 mL/min)
- Methotrexate doses >20 mg/week
- Advanced age
- Hypoalbuminemia
- Concurrent use of other interacting medications (NSAIDs, salicylates, trimethoprim-sulfamethoxazole)
- Dehydration 4
Practical Dosing Recommendations
If concurrent use is necessary:
Continue standard methotrexate monitoring: CBC, liver enzymes (AST/ALT), and creatinine every 1-1.5 months during dose adjustments, then every 1-3 months at stable doses 3
Ensure folic acid supplementation: At least 5 mg weekly (typically 1 mg daily except on methotrexate days) to mitigate toxicity risk 3, 2
No specific dose separation required: Unlike some drug interactions, there is no evidence supporting temporal separation of Dexilant and methotrexate doses
Consider H2-blocker alternative: In several case reports, substituting a histamine H2 blocker (ranitidine, famotidine) for a PPI eliminated the interaction without methotrexate toxicity 1. This represents a reasonable alternative if acid suppression is needed and concerns exist.
Monitoring for Toxicity
Watch for signs of methotrexate toxicity:
- Hematologic: Leukopenia (WBC <3×10⁹/L), thrombocytopenia (platelets <100,000/L), or anemia
- Hepatic: Transaminases >3× upper limit of normal
- Renal: Rising creatinine or decreased creatinine clearance
- Clinical: Mucositis, nausea, diarrhea, unusual fatigue, or new respiratory symptoms 4
Key Caveats
The evidence base for this interaction comes primarily from:
- Case reports and spontaneous adverse event reporting systems
- Studies involving high-dose methotrexate in oncology settings
- Limited prospective data in low-dose methotrexate populations 1
The interaction is not an absolute contraindication for low-dose methotrexate therapy. The decision to use Dexilant concurrently should weigh the patient's need for acid suppression against their individual risk factors for methotrexate toxicity. In patients without significant risk factors using standard low-dose methotrexate regimens, concurrent PPI use with appropriate monitoring is generally acceptable 2, 3.